$2.90-0.01 (-0.34%)
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.
Nasus Pharma Ltd. in the Healthcare sector is trading at $2.90. Wall Street consensus targets $19.67 (3 analysts), implying a +578.2% move over the next 12 months. The stock is currently near its 52-week low of $1.98, remaining 48.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public...